More personalization of communicationsNeed to create more/better content/experiencesHeightened focus on payersIncreased concern over drug pricingIndustry consolidationScrutiny around social mediaImpact of empowered patients/consumersIntensified focus on analytics/ROI/measurementRegulatory changesPrograms that go “beyond the pill”Evolution of EHRsEmphasis on specialty drugs/high-science categoriesAdopting a data-science cultureMore digital experimentationSeizing opportunities around cannabisWorking from homeOngoing fallout from pandemic
Mapping the identity experience in digital health communications
How IX offers greater nuance in engaging with audiences.
The state of DE&I: Moving the needle from commitment to progress
Employees and consumers alike expect companies to take meaningful steps toward creating a more equitable and inclusive future. As shown by the findings from MM+M’s 2022 Diversity Survey, conducted in partnership with IPG Health, progress has been made but we still have a long way to go in the healthcare industry.
How to keep digital pharma marketing relevant in the times of global crises
Nataliya Andreychuk, CEO of Viseven, discusses digital marketing trends and more during her chat with Marc Iskowitz, editor-at-large, MM+M.
Why marketers must make the switch to privacy-safe real-world data for targeting
Developing more precise and brand-exclusive patient segments with higher audience quality.